Altogether, these data indicate that ibandronate did not alter the regulation and the activity of ERs in MCF-7 cells, while it could totally prevent estrogen-induced cell proliferation in ER-positive breast cancer cells, suggesting that it acts downstream of ER-mediated gene transactivation. Here, ESR1 is linked to breast carcinoma.